First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Представленная в разделе информация относится к рецептурным лекарственным препаратам. В ...

Εξερευνήστε ευκαιρίες στη Novartis και στη Sandoz παρακάτω. Για επιπλέον ρόλους στη Novartis Gene Therapies (πρώην AveXis) επισκεφτείτε την Αναζήτηση ...

Atklājiet darba iespējas Novartis. Lai atrastu papildu Novartis Gene Therapies (agrāk AveXis) darba piedāvājumus, apmeklējiet GTx karjeras meklēšanas lapu. Specialty Sales Consultant – Dermatology – ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

İnsanların yaşam kalitesini artırmayı ve ömürlerini uzatmayı hedefleyen yenilikçi tededaviler geliştiriyor ve tedavilerimizi mümkün olduğunca daha çok ihtiyacı olan kişiye ulaştırmayı hedefliyoruz.

Novartis has had a significant footprint in India since 1947, with two legal entities namely, Novartis Healthcare Private Limited, and Novartis India Limited. India is amongst a handful of countries ...

Auditoría y Finanzas BD&L & Strategic Planning Communications & Public Affairs Data and Digital Gerencia Comercial y General Instalaciones y Administración Interns/Students on Novartis Payroll Market ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...